Neumora Therapeutics Inc held its Annual Meeting of Stockholders on May 28, 2025. Stockholders elected Alaa Halawa and Maykin Ho, Ph.D., as Class II directors. Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025. The repricing of certain outstanding stock options under the company's equity incentive plans was approved. Amendments to the company's Amended and Restated Certificate of Incorporation to effect a reverse stock split of its common stock at a ratio ranging from 1-for-5 to 1-for-30 were also approved.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.